Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status

Wiener Klinische Wochenschrift

Volumn 114, Issue 15-16, 2002, Pages 717-724

  Fahrleitner, Astrid ^a   Prenner, Günther ^a   Kniepeiss, Daniela ^a   Iberer, Florian ^a   Tscheliessnigg, Karl Heinz ^a   Piswanger Sölkner, Claudia ^a   Obermayer Pietsch, Barbara ^a   Leb, Georg ^a   Dobnig, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Liver transplantation; Osteoporosis; Osteoprotegerin; Secondary hyperparathyroidism; Serum magnesium

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CYCLOSPORIN A; ESTROGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; OSTEOPROTEGERIN; PREDNISOLONE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DENSITOMETRY; DIET SUPPLEMENTATION; FEMALE; FEMUR NECK; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; MALE; MULTIPLE REGRESSION; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PREVALENCE; SECONDARY HYPERPARATHYROIDISM; SPINE RADIOGRAPHY; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

BONE DENSITY; BONE RESORPTION; CELL DIVISION; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; GLYCOPROTEINS; HUMANS; LINEAR MODELS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; POSTOPERATIVE COMPLICATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPINAL FRACTURES;

EID: 0037200270     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Longterm persistence of low bone density in orthotopic liver transplantation
2. Bone loss at the proximal femur and reduced lean mass following liver transplantation: A longitudinal study
3. Regional bone mineral density after orthotopic liver transplantation
4. Bone loss and turnover in patients with liver transplantation
5. Effect of liver transplantation and immunosuppressive treatment on bone mineral density
6. Bone disease after liver transplantation
7. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis
8. Bone loss after orthotopic liver transplantation
9. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation
10. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study
11. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation
12. Early increases in plasma parathyroid levels following transplantation
13. Bone fractures in liver transplant patients
14. Bone loss after liver transplantation
15. Bone mineral density in the long term after liver transplantation
16. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation
17. Mechanism of bone loss after liver transplantation: A histomorphometric analysis
18. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
19. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
20. Serum osteoprotegerin is a major determinant of bone density and vertebral fracture status in patients after cardiac transplantation
21. The diagnosis of osteoporosis
22. Vertebral fracture assessment using a semiquantitative technique
23. Hypovitaminosis D in medical inpatients
24. Bone disease in liver transplant recipients: Incidence, timing and risk factors
25. Bone mineral status in end-stage liver disease and the effect of liver transplantation
26. Predicting bone loss following orthotopic liver transplantation
27. Free 25-hydroxy vitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxy vitamin D levels
28. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
29. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated
30. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanism of glucocorticoid-induced osteoporosis
31. Serum levels of osteoprotegerin: Effects of glucocorticoid and growth hormone
32. Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis
33. Clinical review 114: Hot topic. The role of receptor activator of nuclear factorkappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
34. Magnesium deficiency and bone loss after cardiac transplantation